Octagon Capital Advisors LP Acquires 5.7% Stake in Context Therapeutics Inc.

On May 14, 2026, Octagon Capital Advisors LP, alongside Octagon Investments Master Fund LP and Dr. Ting Jia, filed a Schedule 13G reporting a new 5.7% ownership stake in Context Therapeutics Inc. (CNTX). The reporting persons disclosed beneficial ownership of 5,250,000 shares of Common Stock as of the event date on March 31, 2026. This represents a significant increase from a previously reported 0.0% position. Octagon Capital Advisors LP serves as the investment manager to the Master Fund, while Dr. Ting Jia is the managing member of Octagon and the principal beneficial owner. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing control of the issuer. All 5,250,000 shares are held with shared voting and dispositive power among the reporting persons. The filing establishes Octagon Capital as a major institutional shareholder in the Philadelphia-based biopharmaceutical company.